Basic Information
| LncRNA/CircRNA Name | CALML3-AS1 |
| Synonyms | NA |
| Region | GRCh38_10:5514244-5526246 |
| Ensemble | ENSG00000205488 |
| Refseq | NR_120496 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, Dual luciferase reporter assay |
| Sample | bladder cancer tissues, cell lines (T24, SW780, J82, HT1376, HCV-29)) |
| Expression Pattern | up-regulated |
| Function Description | we showed that CALML3-AS1 overexpression correlates with advanced staging and an unsatisfactory prognosis.CALML3-AS1 knockdown suppressed BCa cell proliferation, arrested cell-cycle progression and impaired migration and invasion while promoting apoptosis. CALML3-AS1 directly interacts with miR-4316 and inhibits its availability in BCa cells. |
| Pubmed ID | 30177388 |
| Year | 2018 |
| Title | LncRNA CALML3-AS1 promotes tumorigenesis of bladder cancer via regulating ZBTB2 by suppression of microRNA-4316. |
External Links
| Links for CALML3-AS1 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |